Developer docs
API playgroundTry for free, no card

Search company profiles

Actimed Therapeutics

Full company profile

uuid00029i5

Namestring
Actimed Therapeutics
Legal namestring
Actimed Therapeutics Ltd
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Actimed Therapeutics is a privately held, UK-based clinical-stage biopharmaceutical company founded in 2017 by Professors Stefan Anker and Andrew Coats, both world-leading authorities in cachexia and muscle wasting research. The company is developing a proprietary class of small molecules termed Anabolic Catabolic Transforming Agents (ACTAs) that simultaneously target β1-receptor antagonism (anti-catabolic), partial β2-receptor agonism (pro-anabolic), and central 5-HT1a antagonism (appetite and fatigue) for the treatment of muscle wasting disorders. Its lead asset is S-pindolol benzoate (ACM-001.1), a new salt of S-pindolol, being advanced under the FDA IND-approved Phase 2b/3 IMPACT programme in cancer cachexia (NSCLC and CRC) and under the Phase 2a PROACT programme for muscle preservation during and after GLP-1 receptor agonist therapy in obesity. A second ACTA-class candidate, S-oxprenolol (ACM-002), has been granted FDA Orphan Drug Designation in amyotrophic lateral sclerosis (ALS), in which Actimed retains global rights; rights for all other indications have been licensed to Faraday Pharmaceuticals.

The company operates an asset-out-licensing business model as a pre-revenue clinical-stage developer with no commercial products on the market. Cumulative disclosed equity financing totals approximately £19.75m across Seed A, extended Seed B, and a 2023 Series A with extension, with a Series B currently being raised (advised by WG Partners LLP) to fund the IMPACT Phase 2b/3 trial. Revenue mechanics rely on milestone payments and royalties from licensing partners: Mankind Pharma holds exclusive territorial rights to develop, manufacture, and commercialize the cachexia portfolio in India and South Asia (November 2025 deal, commercial terms undisclosed), and Faraday Pharmaceuticals holds global ex-ALS rights to S-oxprenolol ($550,000 upfront, $2.7m near-term milestone, up to $123.5m in total milestones, plus royalties). The product is protected by a global composition-of-matter patent estate for S-pindolol benzoate covering the US, Europe, Japan, Canada, and the UK, with expiry through 2041.

Short descriptiontext

Actimed Therapeutics is a UK-based, clinical-stage biopharmaceutical company developing proprietary ACTA-class small molecules (lead: S-pindolol benzoate) for cancer cachexia, obesity-related muscle loss, and ALS, generating revenue through out-licensing deals and milestone payments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAscot, United Kingdom
HQ citystring
Ascot
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cachexia therapeutics, muscle wasting drugs, cancer cachexia treatment, ALS drug development, GLP-1 muscle preservation
Industry4 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Specialty Biopharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Out-licensing of S-oxprenolol to Faraday Pharmaceuticals
TypeLicensing Royalties
Description

Out-licensed global rights for cancer cachexia and all indications outside of ALS; Actimed received $550,000 upfront (cash + equity), $2.7M near-term milestone eligibility, and up to $123.5M in total potential milestones plus royalties on future sales.

actimedtherapeutics.com
2Regional out-licensing of cachexia products to Mankind Pharma
TypeLicensing Royalties
Description

Exclusive territorial licensing agreement covering India, Bangladesh, Bhutan, Nepal, Sri Lanka and Myanmar for cachexia treatment/prevention; Mankind responsible for development, manufacturing, and sales/marketing costs and pays Actimed (commercial terms not disclosed). Includes S-pindolol benzoate (ACM-001.1) and related Actimed IP/know-how.

actimedtherapeutics.com
3Equity financing (pre-revenue)
TypeSubscription Recurring
Description

Pre-revenue clinical-stage company funded through successive equity rounds: ~£1.25m Seed A (2018), ~£10m seed financing (final tranche Jan 2023), £2.5m extended Seed B (June 2021), £5m Series A (June 2023) plus £4.75m Series A extension (Aug 2023) bringing Series A proceeds to £9.75m; Series B financing being raised to fund IMPACT Phase 2b/3 programme.

prnewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Others, Marketing or Sales
Pricing details1 tier
1Pre-commercial / clinical-stage: no products on market, no pricing disclosed
ModelOtherBilling cadencePay-as-you-go
Notes

No products approved or marketed; commercial pricing not publicly disclosed. Commercial terms of the Mankind Pharma licensing agreement and Faraday Pharmaceuticals licensing agreement not disclosed publicly.

actimedtherapeutics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Actimed Therapeutics is a clinical-stage specialty biopharmaceutical company developing the proprietary Anabolic Catabolic Transforming Agent (ACTA) class of small-molecule therapeutics for cachexia and muscle wasting disorders. Its lead asset, S-pindolol benzoate (ACM-001.1), is being advanced in cancer cachexia (IMPACT Phase 2b/3 programme) and in muscle preservation during/post-GLP-1RA therapy (PROACT Phase 2a), while a second ACTA compound, S-oxprenolol (ACM-002), is retained globally for amyotrophic lateral sclerosis (ALS) with US FDA Orphan Drug Designation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 2.74 kg median weight gain vs 1.09 kg median weight loss in placebo over 4 months in ACT-ONE Phase 2a trial (NSCLC/CRC patients, 10 mg BID)
+4 more records
Product overview1 text field

Actimed Therapeutics is a UK-based clinical-stage specialty pharmaceutical company with a focused two-asset pipeline rather than a platform-plus-modules software architecture. Its core offering is the Anabolic Catabolic Transforming Agent (ACTA) class of small molecules, comprising the lead candidate S-pindolol benzoate (ACM-001.1) and the second asset S-oxprenolol (ACM-002). S-pindolol benzoate is the centrepiece, advanced through the planned Phase 2b/3 IMPACT clinical programme for cancer cachexia (NSCLC and CRC) under FDA IND approval, and through the Phase 2a PROACT programme evaluating muscle preservation during and after GLP-1RA therapy in obesity. S-oxprenolol is retained by Actimed globally for amyotrophic lateral sclerosis (ALS) — where it holds US FDA Orphan Drug Designation — while rights for all other indications (including cancer cachexia) are licensed to Faraday Pharmaceuticals. Geographic expansion is supported by a 2025 licensing agreement granting Mankind Pharma exclusive rights to develop and commercialise Actimed's cachexia products in India and other South Asian territories.

Product and service4 records
1S-pindolol benzoate (ACM-001.1)
CategoryLead clinical-stage small-molecule drug candidate (ACTA class)
Description

New benzoate salt of S-pindolol and Actimed's lead clinical asset. An Anabolic Catabolic Transforming Agent (ACTA) that simultaneously targets β1 receptor antagonism (anti-catabolic), partial β2 receptor agonism (pro-anabolic/muscle growth), and central 5-HT1a antagonism (appetite/fatigue improvement). Being developed for cancer cachexia in NSCLC and CRC and for muscle preservation during/post-GLP-1RA therapy in obesity.

2S-oxprenolol (ACM-002)
CategorySecond clinical-stage small-molecule drug candidate (ACTA class)
Description

Second ACTA-class compound with similar multi-modal pharmacology to S-pindolol. Actimed retains global rights in amyotrophic lateral sclerosis (ALS), where pre-clinical data demonstrated slowed disease progression, improved survival, motor neuron protection, attenuated muscle loss, and increased lean body mass. US FDA Orphan Drug Designation granted in 2024 for ALS. Global rights for cancer cachexia and other indications outside ALS licensed to Faraday Pharmaceuticals.

3IMPACT Programme (Phase 2b/3 clinical development programme)
CategoryClinical development programme (cancer cachexia)
Description

Planned Phase 2b/3 clinical development programme evaluating S-pindolol benzoate in cancer cachexia. Consists of two trials of identical design — IMPACT-NSCLC (non-small cell lung cancer) and IMPACT-CRC (colorectal cancer) — in patients with a diagnosis of cachexia. US IND application approved by FDA in August 2023. First patient dosing planned on completion of financing.

4PROACT Programme (Phase 2a clinical development programme)
CategoryClinical development programme (GLP-1 muscle preservation)
Description

Preserving, Restoring, and Optimising (lean mass and muscle) with ACTAs — a two-part Phase 2a randomised, placebo-controlled clinical trial assessing S-pindolol benzoate in obese patients 1) during and 2) post-GLP-1 receptor agonist (semaglutide) therapy. Up to 48 patients. First patients enrolled June 2025; initial results expected H2 2026. Supported by a preclinical programme in diet-induced obesity models which has completed the in-vivo phase.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierFlagship / CoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-11-21
Description

Strategic licensing agreement granting Mankind Pharma exclusive rights to develop, manufacture and commercialise Actimed's cachexia products (including S-pindolol benzoate / ACM-001.1) in India and South Asian territories (India, Bangladesh, Bhutan, Nepal, Sri Lanka and Myanmar). The licence covers Actimed's patents, know-how and future related patents; Mankind is responsible for all associated development, manufacturing and sales/marketing costs and will commercialise under its own trademarks. The agreement is limited to the field of use in treatment and/or prevention of cachexia. Commercial terms not disclosed.

Strategic tierTactical / Financial AdvisorTypeImplementation/ SI/ Consulting PartnerAnnounced on2023-09-07
Description

London-based Life Sciences specialist advisory firm assisting Actimed with its Series B financing. Partners Nigel Barnes, Satheesh Nadarajah, Robin Stürken involved in advisory role. Series B designed to fund the IMPACT Phase 2b/3 clinical programme to completion.

Strategic tierCore / FlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-04-13
Description

License agreement for S-oxprenolol granting Faraday global rights to develop and commercialise for cancer cachexia and any other indications outside of amyotrophic lateral sclerosis (ALS); Actimed retains global rights to S-oxprenolol in ALS. Deal value: $550,000 upfront (cash + equity), $2.7M near-term milestone eligibility, up to $123.5M in total potential milestones, plus royalties on future sales. S-oxprenolol adds to Faraday's portfolio alongside FDY-5301.

Strategic tierImportant / Ip EnablingTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2020-11-23
Description

Licensing of additional European patent rights to S-oxprenolol in amyotrophic lateral sclerosis (ALS) from Charité – Universitätsmedizin Berlin via BIH Innovations. Covers patent rights in all major European markets including Germany, France, UK, Italy and Spain for treatment of ALS, giving Actimed global rights in this indication.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Licensee of Actimed's S-oxprenolol for cancer cachexia and all non-ALS indications. Develops redox-modulating small molecules for ischemic and muscle-wasting conditions, including FDY-5301; closely comparable in mechanism class and target indication.

TypeBroad incumbent
Description

Swiss specialty pharma that developed anamorelin (Adlumiz/ONO-7643), the only approved pharmaceutical for cancer cachexia in the EU, Japan and Switzerland. Direct overlap with Actimed's lead indication but at a larger, commercial-stage scale.

TypeDirect peer
Description

Clinical-stage US specialty pharma focused on muscle biology and contractility, with programmes in ALS (reldesemtiv, tirasemtiv) and cardiac muscle dysfunction. Comparable in therapeutic focus on muscle performance and small-molecule modality.

TypeEmerging player
Description

US-based clinical-stage biotech developing TCMCB07, a melanocortin-3/4 receptor antagonist for cancer cachexia and GLP-1-related muscle preservation. Direct competitor in both cancer cachexia and GLP-1 lean-mass preservation.

TypeEmerging player
Description

Clinical-stage biotech focused on muscle wasting disorders, including programmes targeting neuromuscular and metabolic indications. Comparable in therapeutic area (muscle wasting) and clinical-stage profile.

6PsiOxus Therapeutics
TypeDirect peer
Description

UK-based clinical-stage oncology biotech previously known as Myotec and co-founded by Actimed's co-founders Stefan Anker and Andrew Coats. Closely comparable in founding lineage, UK clinical-stage focus and gene therapy/immuno-oncology platform.

TypeDirect peer
Description

UK-listed clinical-stage specialty pharma developing ensifentrine for respiratory diseases. Comparable as a UK clinical-stage specialty pharma with similar late-stage clinical profile and direct board overlap (Actimed Executive Chairman David Ebsworth also serves as Verona Pharma Chairman).

TypeEmerging player
Description

French clinical-stage biotech developing NX210c and other programmes targeting sarcopenia, cachexia and muscle wasting disorders. Direct overlap with Actimed's core muscle-wasting focus.

TypeBroad incumbent
Description

US specialty pharma that recently commercialised resmetirom (Rezdiffra) for MASH. Comparable as a clinical-to-commercial specialty pharma with a focused small-molecule pipeline targeting a high-unmet-need specialty indication.

TypeBroad incumbent
Description

Global biopharma with a leadership position in ALS through Qalsody (tofersen) for SOD1-ALS and an active ALS pipeline. Broad incumbent relevant to Actimed's retained S-oxprenolol ALS programme and to the wider neurodegenerative space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Actimed Therapeutics

Clinical-Stage Specialty Biopharmaceuticalsactimedtherapeutics.com

Actimed Therapeutics is a UK-based, clinical-stage biopharmaceutical company developing proprietary ACTA-class small molecules (lead: S-pindolol benzoate) for cancer cachexia, obesity-related muscle loss, and ALS, generating revenue through out-licensing deals and milestone payments.

What Actimed Therapeutics does

Actimed Therapeutics is a privately held, UK-based clinical-stage biopharmaceutical company founded in 2017 by Professors Stefan Anker and Andrew Coats, both world-leading authorities in cachexia and muscle wasting research. The company is developing a proprietary class of small molecules termed Anabolic Catabolic Transforming Agents (ACTAs) that simultaneously target β1-receptor antagonism (anti-catabolic), partial β2-receptor agonism (pro-anabolic), and central 5-HT1a antagonism (appetite and fatigue) for the treatment of muscle wasting disorders. Its lead asset is S-pindolol benzoate (ACM-001.1), a new salt of S-pindolol, being advanced under the FDA IND-approved Phase 2b/3 IMPACT programme in cancer cachexia (NSCLC and CRC) and under the Phase 2a PROACT programme for muscle preservation during and after GLP-1 receptor agonist therapy in obesity. A second ACTA-class candidate, S-oxprenolol (ACM-002), has been granted FDA Orphan Drug Designation in amyotrophic lateral sclerosis (ALS), in which Actimed retains global rights; rights for all other indications have been licensed to Faraday Pharmaceuticals.

The company operates an asset-out-licensing business model as a pre-revenue clinical-stage developer with no commercial products on the market. Cumulative disclosed equity financing totals approximately £19.75m across Seed A, extended Seed B, and a 2023 Series A with extension, with a Series B currently being raised (advised by WG Partners LLP) to fund the IMPACT Phase 2b/3 trial. Revenue mechanics rely on milestone payments and royalties from licensing partners: Mankind Pharma holds exclusive territorial rights to develop, manufacture, and commercialize the cachexia portfolio in India and South Asia (November 2025 deal, commercial terms undisclosed), and Faraday Pharmaceuticals holds global ex-ALS rights to S-oxprenolol ($550,000 upfront, $2.7m near-term milestone, up to $123.5m in total milestones, plus royalties). The product is protected by a global composition-of-matter patent estate for S-pindolol benzoate covering the US, Europe, Japan, Canada, and the UK, with expiry through 2041.

Actimed Therapeutics firmographics

Firmographics
Name
Actimed Therapeutics
Legal name
Actimed Therapeutics Ltd
Website
https://actimedtherapeutics.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Actimed Therapeutics is a UK-based, clinical-stage biopharmaceutical company developing proprietary ACTA-class small molecules (lead: S-pindolol benzoate) for cancer cachexia, obesity-related muscle loss, and ALS, generating revenue through out-licensing deals and milestone payments.
Ownership category
akta.pro rank

Actimed Therapeutics industry classification

Industry
Product category
Clinical-Stage Specialty Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)

Keywords

  • Cachexia therapeutics
  • Muscle wasting drugs
  • Cancer cachexia treatment
  • ALS drug development
  • GLP-1 muscle preservation

Where Actimed Therapeutics is headquartered

Location

Headquarters

HQ city
Ascot
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Actimed Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others, Marketing or Sales

Revenue model

  1. Out-licensing of S-oxprenolol to Faraday Pharmaceuticals: Out-licensed global rights for cancer cachexia and all indications outside of ALS; Actimed received $550,000 upfront (cash + equity), $2.7M near-term milestone eligibility, and up to $123.5M in total potential milestones plus royalties on future sales.
  2. Regional out-licensing of cachexia products to Mankind Pharma: Exclusive territorial licensing agreement covering India, Bangladesh, Bhutan, Nepal, Sri Lanka and Myanmar for cachexia treatment/prevention; Mankind responsible for development, manufacturing, and sales/marketing costs and pays Actimed (commercial terms not disclosed). Includes S-pindolol benzoate (ACM-001.1) and related Actimed IP/know-how.
  3. Equity financing (pre-revenue): Pre-revenue clinical-stage company funded through successive equity rounds: ~£1.25m Seed A (2018), ~£10m seed financing (final tranche Jan 2023), £2.5m extended Seed B (June 2021), £5m Series A (June 2023) plus £4.75m Series A extension (Aug 2023) bringing Series A proceeds to £9.75m; Series B financing being raised to fund IMPACT Phase 2b/3 programme.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goPre-commercial / clinical-stage: no products on market, no pricing disclosed

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Actimed Therapeutics product offering

Product offering

Core offering

Actimed Therapeutics is a clinical-stage specialty biopharmaceutical company developing the proprietary Anabolic Catabolic Transforming Agent (ACTA) class of small-molecule therapeutics for cachexia and muscle wasting disorders. Its lead asset, S-pindolol benzoate (ACM-001.1), is being advanced in cancer cachexia (IMPACT Phase 2b/3 programme) and in muscle preservation during/post-GLP-1RA therapy (PROACT Phase 2a), while a second ACTA compound, S-oxprenolol (ACM-002), is retained globally for amyotrophic lateral sclerosis (ALS) with US FDA Orphan Drug Designation.

Product overview

Actimed Therapeutics is a UK-based clinical-stage specialty pharmaceutical company with a focused two-asset pipeline rather than a platform-plus-modules software architecture. Its core offering is the Anabolic Catabolic Transforming Agent (ACTA) class of small molecules, comprising the lead candidate S-pindolol benzoate (ACM-001.1) and the second asset S-oxprenolol (ACM-002). S-pindolol benzoate is the centrepiece, advanced through the planned Phase 2b/3 IMPACT clinical programme for cancer cachexia (NSCLC and CRC) under FDA IND approval, and through the Phase 2a PROACT programme evaluating muscle preservation during and after GLP-1RA therapy in obesity. S-oxprenolol is retained by Actimed globally for amyotrophic lateral sclerosis (ALS) — where it holds US FDA Orphan Drug Designation — while rights for all other indications (including cancer cachexia) are licensed to Faraday Pharmaceuticals. Geographic expansion is supported by a 2025 licensing agreement granting Mankind Pharma exclusive rights to develop and commercialise Actimed's cachexia products in India and other South Asian territories.

Differentiator

Problem solved

Functional benefit

Products and services

  • S-pindolol benzoate (ACM-001.1) New benzoate salt of S-pindolol and Actimed's lead clinical asset. An Anabolic Catabolic Transforming Agent (ACTA) that simultaneously targets β1 receptor antagonism (anti-catabolic), partial β2 receptor agonism (pro-anabolic/muscle growth), and central 5-HT1a antagonism (appetite/fatigue improvement). Being developed for cancer cachexia in NSCLC and CRC and for muscle preservation during/post-GLP-1RA therapy in obesity.
  • S-oxprenolol (ACM-002) Second ACTA-class compound with similar multi-modal pharmacology to S-pindolol. Actimed retains global rights in amyotrophic lateral sclerosis (ALS), where pre-clinical data demonstrated slowed disease progression, improved survival, motor neuron protection, attenuated muscle loss, and increased lean body mass. US FDA Orphan Drug Designation granted in 2024 for ALS. Global rights for cancer cachexia and other indications outside ALS licensed to Faraday Pharmaceuticals.
  • IMPACT Programme (Phase 2b/3 clinical development programme) Planned Phase 2b/3 clinical development programme evaluating S-pindolol benzoate in cancer cachexia. Consists of two trials of identical design — IMPACT-NSCLC (non-small cell lung cancer) and IMPACT-CRC (colorectal cancer) — in patients with a diagnosis of cachexia. US IND application approved by FDA in August 2023. First patient dosing planned on completion of financing.
  • PROACT Programme (Phase 2a clinical development programme) Preserving, Restoring, and Optimising (lean mass and muscle) with ACTAs — a two-part Phase 2a randomised, placebo-controlled clinical trial assessing S-pindolol benzoate in obese patients 1) during and 2) post-GLP-1 receptor agonist (semaglutide) therapy. Up to 48 patients. First patients enrolled June 2025; initial results expected H2 2026. Supported by a preclinical programme in diet-induced obesity models which has completed the in-vivo phase.

Quantifiable outcome

  • 2.74 kg median weight gain vs 1.09 kg median weight loss in placebo over 4 months in ACT-ONE Phase 2a trial (NSCLC/CRC patients, 10 mg BID)
  • +4 more outcomes

Companies that use Actimed Therapeutics

Customer profile

Segments4 records

Ideal customer profiles3 records

Actimed Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Actimed Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship / core, tactical / financial advisor, core / flagship and important / ip enabling.

  • Mankind Pharma Limitedflagship / coreOEM/ Whitelabel/ Licensing Partner · 21 November 2025Strategic licensing agreement granting Mankind Pharma exclusive rights to develop, manufacture and commercialise Actimed's cachexia products (including S-pindolol benzoate / ACM-001.1) in India and South Asian territories (India, Bangladesh, Bhutan, Nepal, Sri Lanka and Myanmar). The licence covers Actimed's patents, know-how and future related patents; Mankind is responsible for all associated development, manufacturing and sales/marketing costs and will commercialise under its own trademarks. The agreement is limited to the field of use in treatment and/or prevention of cachexia. Commercial terms not disclosed.
  • WG Partners LLPtactical / financial advisorImplementation/ SI/ Consulting Partner · 7 September 2023London-based Life Sciences specialist advisory firm assisting Actimed with its Series B financing. Partners Nigel Barnes, Satheesh Nadarajah, Robin Stürken involved in advisory role. Series B designed to fund the IMPACT Phase 2b/3 clinical programme to completion.
  • Faraday Pharmaceuticals, Inc.core / flagshipOEM/ Whitelabel/ Licensing Partner · 13 April 2021License agreement for S-oxprenolol granting Faraday global rights to develop and commercialise for cancer cachexia and any other indications outside of amyotrophic lateral sclerosis (ALS); Actimed retains global rights to S-oxprenolol in ALS. Deal value: $550,000 upfront (cash + equity), $2.7M near-term milestone eligibility, up to $123.5M in total potential milestones, plus royalties on future sales. S-oxprenolol adds to Faraday's portfolio alongside FDY-5301.
  • Charité – Universitätsmedizin Berlinimportant / ip enablingOEM/ Whitelabel/ Licensing Partner · 23 November 2020Licensing of additional European patent rights to S-oxprenolol in amyotrophic lateral sclerosis (ALS) from Charité – Universitätsmedizin Berlin via BIH Innovations. Covers patent rights in all major European markets including Germany, France, UK, Italy and Spain for treatment of ALS, giving Actimed global rights in this indication.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Actimed Therapeutics competitors and assessment

Company assessment

Direct peers

  • Faraday Pharmaceuticals: Licensee of Actimed's S-oxprenolol for cancer cachexia and all non-ALS indications. Develops redox-modulating small molecules for ischemic and muscle-wasting conditions, including FDY-5301; closely comparable in mechanism class and target indication.
  • Cytokinetics: Clinical-stage US specialty pharma focused on muscle biology and contractility, with programmes in ALS (reldesemtiv, tirasemtiv) and cardiac muscle dysfunction. Comparable in therapeutic focus on muscle performance and small-molecule modality.
  • PsiOxus Therapeutics: UK-based clinical-stage oncology biotech previously known as Myotec and co-founded by Actimed's co-founders Stefan Anker and Andrew Coats. Closely comparable in founding lineage, UK clinical-stage focus and gene therapy/immuno-oncology platform.
  • Verona Pharma: UK-listed clinical-stage specialty pharma developing ensifentrine for respiratory diseases. Comparable as a UK clinical-stage specialty pharma with similar late-stage clinical profile and direct board overlap (Actimed Executive Chairman David Ebsworth also serves as Verona Pharma Chairman).

Broad incumbents

  • Helsinn Group: Swiss specialty pharma that developed anamorelin (Adlumiz/ONO-7643), the only approved pharmaceutical for cancer cachexia in the EU, Japan and Switzerland. Direct overlap with Actimed's lead indication but at a larger, commercial-stage scale.
  • Madrigal Pharmaceuticals: US specialty pharma that recently commercialised resmetirom (Rezdiffra) for MASH. Comparable as a clinical-to-commercial specialty pharma with a focused small-molecule pipeline targeting a high-unmet-need specialty indication.
  • Biogen: Global biopharma with a leadership position in ALS through Qalsody (tofersen) for SOD1-ALS and an active ALS pipeline. Broad incumbent relevant to Actimed's retained S-oxprenolol ALS programme and to the wider neurodegenerative space.

Emerging players

  • Endevica Bio: US-based clinical-stage biotech developing TCMCB07, a melanocortin-3/4 receptor antagonist for cancer cachexia and GLP-1-related muscle preservation. Direct competitor in both cancer cachexia and GLP-1 lean-mass preservation.
  • Epirium Bio: Clinical-stage biotech focused on muscle wasting disorders, including programmes targeting neuromuscular and metabolic indications. Comparable in therapeutic area (muscle wasting) and clinical-stage profile.
  • Axoltis Pharma: French clinical-stage biotech developing NX210c and other programmes targeting sarcopenia, cachexia and muscle wasting disorders. Direct overlap with Actimed's core muscle-wasting focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Actimed Therapeutics compliance and trust

Trust signal

Compliance4 records

Actimed Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Actimed Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

Actimed Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Actimed Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Actimed Therapeutics

What does Actimed Therapeutics do?

Actimed Therapeutics is a clinical-stage specialty biopharmaceutical company developing the proprietary Anabolic Catabolic Transforming Agent (ACTA) class of small-molecule therapeutics for cachexia and muscle wasting disorders. Its lead asset, S-pindolol benzoate (ACM-001.1), is being advanced in cancer cachexia (IMPACT Phase 2b/3 programme) and in muscle preservation during/post-GLP-1RA therapy (PROACT Phase 2a), while a second ACTA compound, S-oxprenolol (ACM-002), is retained globally for amyotrophic lateral sclerosis (ALS) with US FDA Orphan Drug Designation.

Is Actimed Therapeutics a public or private company?

Actimed Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Actimed Therapeutics founded?

Actimed Therapeutics was founded in 2017. It employs 11 to 50 people.

Where is Actimed Therapeutics based?

Actimed Therapeutics is headquartered in Ascot, United Kingdom, in the Europe region.

How does Actimed Therapeutics make money?

Three revenue lines are on record. Out-licensing of S-oxprenolol to Faraday Pharmaceuticals are the primary driver. The others are regional out-licensing of cachexia products to Mankind Pharma and equity financing (pre-revenue).

Who are Actimed Therapeutics's main competitors?

Direct peers on record are Faraday Pharmaceuticals, Cytokinetics, PsiOxus Therapeutics and Verona Pharma. Broad incumbents are Helsinn Group, Madrigal Pharmaceuticals and Biogen. Emerging players are Endevica Bio, Epirium Bio and Axoltis Pharma.

Does Actimed Therapeutics have an API?

No public API is recorded for Actimed Therapeutics.

What industry is Actimed Therapeutics in?

Actimed Therapeutics's product category is Clinical-Stage Specialty Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingActimed Therapeutics Completes Recruitment for PROACT Phase 2a Study Evaluating S-pindolol benzoate (ACM 001.1) in Obese Adults During and After Semaglutide TherapyActimed Therapeutics completed recruitment for its PROACT Phase 2a study evaluating S-pindolol benzoate in obese adults during and after semaglutide therapy. The trial enrolled over 100 patients, the planned sample size, and is designed to assess preservation of lean body mass during and after GLP-1RA treatment.The Manila TimesActimed Therapeutics Reacquires Global Rights to S-oxprenolol, Broadening Pipeline OpportunityActimed Therapeutics has reacquired the exclusive global rights to S-oxprenolol from Faraday Pharmaceuticals, allowing it to regain full control over the development and commercialization of the product. This transaction is significant as S-oxprenolol exhibits potential in treating muscle wasting associated with amyotrophic lateral sclerosis (ALS) and other disorders. Actimed aims to initiate a clinical development program for the drug after completing necessary preparatory work.European BiotechnologyActimed retrieves ALS drug after Faraday collapseUK biotech Actimed Therapeutics has regained global rights to the experimental drug S-oxprenolol from the collapsed Faraday Pharmaceuticals, allowing Actimed to control its development across various muscle-wasting conditions, including ALS. Although the drug has yet to enter clinical development, the company plans to initiate a clinical program focused initially on ALS after completing necessary preliminary work. Actimed's reclaiming of rights follows Faraday's operational cessation after its leading drug failed in clinical trials.The Pharma LetterActimed regains global rights to S-oxprenololActimed Therapeutics, a UK-based pharmaceutical company, has regained exclusive global rights to the drug S-oxprenolol from US biotech Faraday Pharmaceuticals. The original licensing agreement in 2021 gave Faraday rights to develop and commercialize the drug for certain indications.GlobeNewswireActimed Therapeutics Reacquires Global Rights to S-oxprenolol, Broadening Pipeline OpportunityActimed Therapeutics, a UK-based clinical stage specialty pharmaceutical company, has regained exclusive global rights to the drug candidate S-oxprenolol from Faraday Pharmaceuticals, reversing the 2021 licensing agreement under which Faraday held rights for all indications except amyotrophic lateral sclerosis. The transaction consolidates full development, manufacturing, and commercialisation rights under Actimed, enabling the company to pursue clinical development initially in ALS, where S-oxprenolol holds orphan drug designation, while also evaluating potential in other muscle wasting disorders.FierceBiotechActimed gets back rights to wasting disease drug, ending $126M deal with FaradayActimed Therapeutics has regained full worldwide rights to its S-oxprenolol drug for wasting diseases from Faraday Pharmaceuticals, ending a 2021 licensing agreement that included up to $126.2 million in potential milestone payments. The London-based biotech will now hold complete development, manufacturing, and commercialization control, enabling it to pursue ALS and other muscle-wasting indications without partner constraints. Actimed plans to initiate clinical development pending completion of CMC work, having secured orphan drug designation for the ALS indication.GlobeNewswireActimed Therapeutics Reacquires Global Rights to S-oxprenolol, Broadening Pipeline OpportunityActimed Therapeutics regained exclusive global rights to S-oxprenolol from Faraday Pharmaceuticals, holding full development, manufacturing, and commercialization rights worldwide. The drug has orphan drug designation for ALS, and Actimed plans to initiate clinical development after CMC work is completed. The company is also evaluating potential in other muscle wasting disorders.GlobeNewswireActimed Therapeutics Strengthens Board with Appointment of Dr. Anders UllmanActimed Therapeutics Ltd announced the appointment of Dr. Anders Ullman to its Board of Directors, effective 30 July 2026. Dr. Ullman brings over 30 years of international pharmaceutical experience, having served as Head of Research & Development and Chief Medical Officer at Sobi, and held senior leadership positions at companies including AstraZeneca, Bayer, Takeda, and Baxter. The appointment is expected to support Actimed's clinical programs developing treatments for cancer cachexia, obesity, and other muscle wasting disorders.BioSpaceActimed Therapeutics Strengthens Board with Appointment of Dr. Anders UllmanActimed Therapeutics appointed Dr. Anders Ullman to its Board of Directors, a physician and pharmaceutical executive with over 30 years of experience. He previously served as Head of R&D and Chief Medical Officer at AstraZeneca and other companies. The appointment comes as Actimed advances its clinical programs for cancer cachexia and ALS.GlobeNewswireActimed Therapeutics to Highlight Advancing Clinical Pipeline with New Data Presentations at 18th Annual Conference on Sarcopenia, Cachexia, and Wasting DisordersActimed Therapeutics will present data on its cancer cachexia and muscle wasting treatments at the SCWD conference in Rome, December 11-13, 2025. The company will discuss S-pindolol benzoate's development in cancer cachexia and its effect on lean mass during GLP-1RA therapy, and preclinical data on S-oxprenolol for ALS. Actimed plans to advance S-oxprenolol development in 2026.